A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease

Alzheimer's disease is the most common neurodegenerative disease of the central nervous system characterized by a progressive loss in memory and deterioration of cognitive functions. In this study the transgenic mouse TgCRND8, which encodes a mutant form of the amyloid precursor protein 695 with both the Swedish and Indiana mutations and develops extracellular amyloid beta-peptide deposits as early as 2-3 months, was investigated. Extract from eight brain regions (cortex, frontal cortex, cerebellum, hippocampus, olfactory bulb, pons, midbrain and striatum) were studied using (1)H NMR spectroscopy. Analysis of the NMR spectra discriminated control from APP695 tissues in hippocampus, cortex, frontal cortex, midbrain and cerebellum, with hippocampal and cortical region being most affected. The analysis of the corresponding loading plots for these brain regions indicated a decrease in N-acetyl-L-aspartate, glutamate, glutamine, taurine (exception hippocampus), gamma-amino butyric acid, choline and phosphocholine (combined resonances), creatine, phosphocreatine and succinate in hippocampus, cortex, frontal cortex (exception gamma-amino butyric acid) and midbrain of affected animals. An increase in lactate, aspartate, glycine (except in midbrain) and other amino acids including alanine (exception frontal cortex), leucine, iso-leucine, valine and water soluble free fatty acids (0.8-0.9 and 1.2-1.3 ppm) were observed in the TgCRND8 mice. Our findings demonstrate that the perturbations in metabolism are more widespread and include the cerebellum and midbrain. Furthermore, metabolic perturbations are associated with a wide range of metabolites which could improve the diagnosis and monitoring of the progression of Alzheimer's disease.

[1]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[2]  O. Petroff,et al.  Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. , 1995, Magnetic resonance imaging.

[3]  G. Fein,et al.  Reduced brain N‐acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus‐seropositive individuals , 1993, Neurology.

[4]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[5]  Clifford R Jack,et al.  Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. McKhann,et al.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease , 2008, Nature Medicine.

[7]  R. Huxtable.  Taurine in the central nervous system and the mammalian actions of taurine , 1989, Progress in Neurobiology.

[8]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[9]  C. Morissette,et al.  Inflammation occurs early during the Aβ deposition process in TgCRND8 mice , 2004, Neurobiology of Aging.

[10]  V. Govindaraju,et al.  Proton NMR chemical shifts and coupling constants for brain metabolites , 2000, NMR in biomedicine.

[11]  D. Selkoe,et al.  In search of gamma-secretase: presenilin at the cutting edge. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Pettegrew,et al.  Analysis of magnetic resonance spectra by mole percent: Comparison to absolute units , 1994, Neurobiology of Aging.

[13]  N. Herrmann,et al.  Behavioral correlates of GABAergic disruption in Alzheimer's disease , 2006, International Psychogeriatrics.

[14]  Julian L Griffin,et al.  High Resolution 1H NMR-based Metabolomics Indicates a Neurotransmitter Cycling Deficit in Cerebral Tissue from a Mouse Model of Batten Disease* , 2005, Journal of Biological Chemistry.

[15]  J. E. Jackson.  A User's Guide to Principal Components , 1991 .

[16]  M. Garcia-Alloza,et al.  Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease , 2006, Neurobiology of Aging.

[17]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[18]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[19]  J. Edward Jackson,et al.  A User's Guide to Principal Components. , 1991 .

[20]  L. Mucke,et al.  Reduction in Mitochondrial Superoxide Dismutase Modulates Alzheimer's Disease-Like Pathology and Accelerates the Onset of Behavioral Changes in Human Amyloid Precursor Protein Transgenic Mice , 2006, The Journal of Neuroscience.

[21]  D. Selkoe,et al.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.

[22]  D. Westaway,et al.  New developments in animal models of Alzheimer’s disease , 2001, Current neurology and neuroscience reports.

[23]  P. Jolles,et al.  An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains , 2004, Experimental Brain Research.

[24]  K. Ishii,et al.  Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  S. Turner,et al.  Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.

[26]  J. Vallat,et al.  [Role of glutamate and excitotoxicity in neurologic diseases]. , 1996, Revue neurologique.

[27]  G. Feng,et al.  Imaging Neuronal Subsets in Transgenic Mice Expressing Multiple Spectral Variants of GFP , 2000, Neuron.

[28]  J. Blass.  Pathophysiology of the Alzheimer's syndrome , 1993 .

[29]  D. Kondziella,et al.  Neuronal glial interaction in different neurological diseases studied by ex vivo 13C NMR spectroscopy , 2003, NMR in biomedicine.

[30]  S. Wold,et al.  Multivariate Data Analysis in Chemistry , 1984 .

[31]  Morris H. Baslow,et al.  N-Acetylaspartate in the Vertebrate Brain: Metabolism and Function , 2003, Neurochemical Research.

[32]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[33]  P. Antuono,et al.  Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1H-MRS at 0.5 T , 2001, Neurology.

[34]  G. E. Alexander,et al.  Brain metabolite concentration and dementia severity in Alzheimer’s disease , 2001, Neurology.

[35]  J. Blass.  Metabolic alterations common to neural and non‐neural cells in alzheimer's disease , 1993, Hippocampus.

[36]  Yoo-Hun Suh,et al.  Amyloid Precursor Protein, Presenilins, and α-Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease , 2002, Pharmacological Reviews.

[37]  A. Schousboe,et al.  Trafficking between glia and neurons of TCA cycle intermediates and related metabolites , 1997, Glia.

[38]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. , 2006, Journal of Alzheimer's disease : JAD.

[39]  Ji-Kyung Choi,et al.  Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile , 2004, Brain Research.

[40]  E. Zimmerman,et al.  1H MR spectroscopy using TE averaged PRESS: A more sensitive technique to detect neurodegeneration associated with Alzheimer's disease , 2005, Magnetic resonance in medicine.

[41]  P. Doraiswamy,et al.  Magnetic resonance spectroscopy in Alzheimer's disease: focus on N‐acetylaspartate , 2000, Acta neurologica Scandinavica. Supplementum.

[42]  Randall S. Jones,et al.  1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia , 2004, Neurological research.

[43]  P. Adlard,et al.  Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging , 2009, Neurobiology of Aging.

[44]  C. Gottfries,et al.  Membrane Lipids, Selectively Diminished in Alzheimer Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination in Late‐Onset Form (Type II) , 1994, Journal of neurochemistry.

[45]  D. Kültz,et al.  Regulation of gene expression by hypertonicity. , 1997, Annual review of physiology.

[46]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[47]  D. Borchelt,et al.  Transgenic Mouse Models of Alzheimer's Disease and Amyotrophic Lateral Sclerosis , 1998, Brain pathology.

[48]  Dieter Suter,et al.  Two-dimensional chemical exchange and cross-relaxation spectroscopy of coupled nuclear spins , 1981 .

[49]  S. Williams,et al.  A comparison of cell and tissue extraction techniques using high‐resolution 1H‐NMR spectroscopy , 2002, NMR in biomedicine.

[50]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[51]  K O Lim,et al.  In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. , 1999, Archives of general psychiatry.

[52]  F. Fonnum.  Glutamate: A Neurotransmitter in Mammalian Brain , 1984, Journal of neurochemistry.

[53]  J. Pettegrew,et al.  Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. , 1996, Journal of lipid mediators and cell signalling.

[54]  V. Calabrese.  Biochemistry and the Central Nervous System , 1986 .

[55]  P. Adlard,et al.  Morphologically distinct plaque types differentially affect dendritic structure and organisation in the early and late stages of Alzheimer's disease , 2002, Acta Neuropathologica.

[56]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[57]  D. Selkoe,et al.  In search of γ-secretase: Presenilin at the cutting edge , 2000 .

[58]  Jason Eriksen,et al.  A decade of modeling Alzheimer's disease in transgenic mice. , 2006, Trends in genetics : TIG.

[59]  O. Andreassen,et al.  Nonlinear Decrease over Time in N‐Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice , 2000, Journal of neurochemistry.

[60]  S. Hoyer,et al.  Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.

[61]  F. Jessen,et al.  A Comparative Study of the Different N-Acetylaspartate Measures of the Medial Temporal Lobe in Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[62]  J. Blass,et al.  Abnormalities of mitochondrial enzymes in Alzheimer disease , 1998, Journal of Neural Transmission.

[63]  Fahmeed Hyder,et al.  In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. , 2003, Annual review of physiology.

[64]  Henry McIlwain.  Biochemistry and the Central Nervous System , 1955 .

[65]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[66]  J. Pettegrew,et al.  Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. , 1988, Archives of neurology.

[67]  D. Gauguier,et al.  Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.

[68]  D. Rubinsztein.  The genetics of Alzheimer's disease , 1997, Progress in Neurobiology.

[69]  S. Hoyer.  Models of Alzheimer's disease: cellular and molecular aspects. , 1997, Journal of neural transmission. Supplementum.

[70]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[71]  A Hofman,et al.  Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. , 1998, Human molecular genetics.

[72]  D. Attwell.  Glia and neurons in dialogue , 1994, Nature.

[73]  R. Rissman,et al.  GABAA receptors in aging and Alzheimer’s disease , 2007, Journal of neurochemistry.

[74]  D. Selkoe,et al.  The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.

[75]  S D Chen,et al.  [Amyloid precursor protein and Alzheimer's disease]. , 1993, Sheng li ke xue jin zhan [Progress in physiology].

[76]  John C. Lindon,et al.  NMR Spectroscopy of Biofluids , 1999 .

[77]  E. Tangalos,et al.  Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.